METTL3 and chronic myelogenous leukemia, BCR-ABL1 positive: In CML, TKI resistance always makes it more difficult to cure patients with CML, while METTL3 has been found to affect the apoptosis, proliferation, and viability of CML cells with higher expression (60, 61, 68, 70).